Pacalis Therapeutics announced as joint winner of Early-Stage Innovation Forum at 2024 AusBiotech

4 November 2024

Chief Scientific Adviser, Professor Chris Langmead collecting the joint winner award from the Early-Stage Innovation Forum at the 2024 AusBiotech Conference.

Congratulations to Dr David Bibby, CEO and Co-Founder of Pacalis Therapeutics Pty Ltd who was announced as the joint winner of the Early-Stage Innovation Forum at the 2024 AusBiotech annual meeting, held in Melbourne last week.

Special mention to Chief Scientific Adviser, Professor Chris Langmead for collecting the award.

It was a wonderful opportunity to pitch the efforts of Pacalis Therapeutics to this knowledgeable audience and to receive positive recognition for the research that is currently being undertaking by the team.

Pacalis Therapeutics is developing first-in-class therapeutics for conditions such as Major Depressive Disorder (MDD), Substance Use Disorder (SUD), and Post-Traumatic Stress Disorder (PTSD).